NeoGenomics stock plunges more than 20% as CEO departs after disappointing quarter
March 28, 2022 at 16:58 PM EDT
NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, sending shares down more than 20% in after-hours trading.
